PYC - Ticker AI Digest

Physiomics Plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (PYC) 1
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by Numab
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for drug development, has been awarded a new contract by its long-standing client, Numab Therapeutics AG. The project involves using modelling and simulation to support the pre-clinical development of a multi-specific antibody targeting autoimmune diseases. Physiomics will develop a mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) model to optimize dosing for preclinical and clinical studies. The project is expected to be completed within the financial year ending 2026. This contract highlights the growing importance of Model Informed Drug Development (MIDD) in the drug development lifecycle. Dr. Peter Sargent, CEO of Physiomics, expressed satisfaction with the continued collaboration with Numab Therapeutics, emphasizing support for their therapeutic antibody pipeline in oncology and autoimmune indications. Physiomics has a proven track record, having contributed to over 100 commercial projects with clients including Merck KGaA, Astellas, and CRUK. The announcement was made via the London Stock Exchanges RNS news service on December 11, 2025.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 3
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by Numab
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for drug development, has been awarded a new contract by its long-standing client, Numab Therapeutics AG. The project involves using modelling and simulation to support the pre-clinical development of a multi-specific antibody targeting autoimmune diseases. Physiomics will develop a mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) model to optimize dosing for preclinical and clinical studies. The project is expected to be completed within the financial year ending 2026. This contract highlights the growing importance of Model Informed Drug Development (MIDD) in the drug development lifecycle. Dr. Peter Sargent, CEO of Physiomics, expressed satisfaction with the continued collaboration with Numab Therapeutics, emphasizing support for their therapeutic antibody pipeline in oncology and autoimmune indications. Physiomics has a proven track record, having contributed to over 100 commercial projects with clients including Merck KGaA, Astellas, and CRUK. The announcement was made via the London Stock Exchanges RNS news service on December 11, 2025.
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by GARDP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics, has been awarded a new contract by the GARDP Foundation, a not-for-profit organization focused on developing new antibiotic treatments. The contract involves providing expert consultancy to optimize the design of an efficacy trial for GARDPs Serious Bacterial Infections (SBIs) program. The project, set to begin in January 2026 and complete within three months, marks Physiomics second major client in its Biometrics department and its third Biometrics contract since launching the service line earlier in 2025. This partnership expands Physiomics expertise into the infectious disease therapeutic area, aligning with the companys growth objectives. CEO Dr. Peter Sargent highlighted the contract as a significant milestone, surpassing initial projections and underscoring the potential of the Biometrics service line. Physiomics continues to support biotech and pharma companies in de-risking drug development through advanced computational tools and data-driven insights.
PYC 06:01
Physiomics Plc
Physiomics Awarded Two New Contracts
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for therapeutic development, announced the award of two new contracts totaling £29,750. The first contract, valued at £13,600, extends a partnership with a UK-based AI-driven biotech firm, utilizing Physiomics Virtual Tumour Platform to guide dosing for an oncology drug. The second contract, worth £16,150, involves collaborating with a partner to support a UK biotech client in renal disease therapy development through modelling and simulation strategies. Both projects are expected to complete within a month. Dr. Peter Sargent, CEO, highlighted the significance of these contracts in demonstrating repeat business and expanding the companys therapeutic reach beyond oncology. Physiomics continues to leverage its expertise and proprietary technologies to support over 100 commercial projects with clients like Merck KGaA, Astellas, and CRUK.
**Key Points**
Two new contracts awardedtotaling £29750.
Contract 1£13,600 for oncology drug dosing with an existing client.
Contract 2£16,150 for renal disease therapy development with a new client.
Both projects to complete within a month.
Highlights repeat business and diversification into new therapeutic areas.
Physiomics supports over 100 commercial projects with cutting-edge technologies.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
PYC 15:32
Physiomics Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 6
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by Numab
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for drug development, has been awarded a new contract by its long-standing client, Numab Therapeutics AG. The project involves using modelling and simulation to support the pre-clinical development of a multi-specific antibody targeting autoimmune diseases. Physiomics will develop a mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) model to optimize dosing for preclinical and clinical studies. The project is expected to be completed within the financial year ending 2026. This contract highlights the growing importance of Model Informed Drug Development (MIDD) in the drug development lifecycle. Dr. Peter Sargent, CEO of Physiomics, expressed satisfaction with the continued collaboration with Numab Therapeutics, emphasizing support for their therapeutic antibody pipeline in oncology and autoimmune indications. Physiomics has a proven track record, having contributed to over 100 commercial projects with clients including Merck KGaA, Astellas, and CRUK. The announcement was made via the London Stock Exchanges RNS news service on December 11, 2025.
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by GARDP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics, has been awarded a new contract by the GARDP Foundation, a not-for-profit organization focused on developing new antibiotic treatments. The contract involves providing expert consultancy to optimize the design of an efficacy trial for GARDPs Serious Bacterial Infections (SBIs) program. The project, set to begin in January 2026 and complete within three months, marks Physiomics second major client in its Biometrics department and its third Biometrics contract since launching the service line earlier in 2025. This partnership expands Physiomics expertise into the infectious disease therapeutic area, aligning with the companys growth objectives. CEO Dr. Peter Sargent highlighted the contract as a significant milestone, surpassing initial projections and underscoring the potential of the Biometrics service line. Physiomics continues to support biotech and pharma companies in de-risking drug development through advanced computational tools and data-driven insights.
PYC 15:32
Physiomics Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
PYC 06:01
Physiomics Plc
Physiomics Awarded Two New Contracts
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for therapeutic development, announced the award of two new contracts totaling £29,750. The first contract, valued at £13,600, extends a partnership with a UK-based AI-driven biotech firm, utilizing Physiomics Virtual Tumour Platform to guide dosing for an oncology drug. The second contract, worth £16,150, involves collaborating with a partner to support a UK biotech client in renal disease therapy development through modelling and simulation strategies. Both projects are expected to complete within a month. Dr. Peter Sargent, CEO, highlighted the significance of these contracts in demonstrating repeat business and expanding the companys therapeutic reach beyond oncology. Physiomics continues to leverage its expertise and proprietary technologies to support over 100 commercial projects with clients like Merck KGaA, Astellas, and CRUK.
**Key Points**
Two new contracts awardedtotaling £29750.
Contract 1£13,600 for oncology drug dosing with an existing client.
Contract 2£16,150 for renal disease therapy development with a new client.
Both projects to complete within a month.
Highlights repeat business and diversification into new therapeutic areas.
Physiomics supports over 100 commercial projects with cutting-edge technologies.
PYC 06:01
Physiomics Plc
Board Changes
PYC 14:44
Physiomics Plc
Result of AGM

AI Crunch

Single-Ticker AI Crunch
PYC signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Physiomics Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full PYC AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for PYC on 2025-12-11.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
2266043
Enterprise Value
1699233
Public Float
48.12
Broker Target
0.2
Shares Out
453208718
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BDR6W943
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-04
Net Debt
-461242.0
Cash
461242.0
EPS
-
Net Income
-415254.0
Revenue
784005.0
Enterprise Value
1699233
Trailing PE
-
Forward PE
6.1652
Price Sales TTM
2.2477
Price Book MRQ
5.766
EV Revenue
2.1081
EV EBITDA
-8.7624

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
21.2662
Institutions As Of
2026-03-24
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
1
Sale Director Dealing
0
Purchase TR1
3
Sale TR1
2
Broker Coverage Rows
0
Institution Holders Tracked
4
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit PYC.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-12-11 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Physiomics Plc has fresh news flow feeding the chart narrative.
AI Charts Studio
PYC Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-12-11 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 51.72%
RSI Gauge
Price Change
AI Forecast